- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 10.04. | CARSGEN-B (02171): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, ... | - | HKEx | ||
| 10.04. | CARSGEN-B (02171): ANNUAL REPORT 2025 | - | HKEx | ||
| 09.03. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE 2019 EQUITY INCENTIVE PLAN | 1 | HKEx | ||
| 09.03. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST UNDER THE SOUTHBOUND STOCK CONNECT | 1 | HKEx | ||
| 06.03. | CARsgen Therapeutics Announces 2025 Annual Results | 302 | PR Newswire | SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 06.03. | CARSGEN-B (02171): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ... | - | HKEx | ||
| 24.02. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.02. | CARsgen to Expand Commercial Manufacturing Base in Shanghai | 1 | Contract Pharma | ||
| 13.02. | CARsgen Therapeutics: CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai | 173 | PR Newswire | SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 13.02. | CARSGEN-B (02171): DISCLOSABLE TRANSACTION - ENTERING INTO THE STRATEGIC COOPERATION AGREEMENTS | 1 | HKEx | ||
| 26.01. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 2 | HKEx | ||
| 23.01. | CARSGEN-B (02171): (REVISED) NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 23.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.12.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY AND SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER | 2 | HKEx | ||
| 11.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,060 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| ERASCA | 9,080 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie vor Schicksalszone: Durchbruch oder Absturz? | © Foto: fn SymbolbildEvotec hat zuletzt für Aufsehen gesorgt. Innerhalb weniger Wochen kletterte die Aktie um fast 50 Prozent nach oben, doch jetzt nähert sie sich einer Marke, die über vieles entscheiden... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,350 | 0,00 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BIONTECH | 87,00 | -0,17 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,390 | 0,00 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ADMA BIOLOGICS | 10,600 | -2,66 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| APOGEE THERAPEUTICS | 82,03 | -3,79 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters | ||
| COGENT BIOSCIENCES | 35,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 26,950 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,810 | -2,12 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| KINIKSA PHARMACEUTICALS | 53,00 | -1,58 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 15,780 | +23,18 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,415 | -4,10 % | Dyne Therapeutics vor Quartalszahlen: Markteinführung von DMD-Therapie im Fokus |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.